Compare RSVR & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RSVR | CTMX |
|---|---|---|
| Founded | 2007 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Movies/Entertainment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 642.8M | 716.9M |
| IPO Year | 2020 | 2015 |
| Metric | RSVR | CTMX |
|---|---|---|
| Price | $9.27 | $2.79 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 10 |
| Target Price | $11.50 | ★ $12.10 |
| AVG Volume (30 Days) | 49.7K | ★ 3.5M |
| Earning Date | 05-27-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 8.33 | N/A |
| EPS | ★ 0.13 | N/A |
| Revenue | ★ $175,664,491.00 | $76,201,000.00 |
| Revenue This Year | $10.95 | N/A |
| Revenue Next Year | $4.16 | $7.61 |
| P/E Ratio | $71.92 | ★ $22.58 |
| Revenue Growth | ★ 10.69 | N/A |
| 52 Week Low | $7.07 | $1.90 |
| 52 Week High | $13.39 | $8.21 |
| Indicator | RSVR | CTMX |
|---|---|---|
| Relative Strength Index (RSI) | 42.75 | 29.17 |
| Support Level | $7.31 | N/A |
| Resistance Level | $10.34 | $3.93 |
| Average True Range (ATR) | 0.34 | 0.22 |
| MACD | -0.02 | -0.07 |
| Stochastic Oscillator | 55.80 | 2.05 |
Reservoir Media Inc is an independent music company. The company operates a music publishing business, a recorded music business, a management business, and a rights management entity in the Middle East. The company's segments include Music Publishing and Recorded Music. It generates the maximum of its revenue from the U.S. Music Publishing segment engaged in the acquisition of interests in music catalogs to earn royalties and signing songwriters to agreements of future delivery of songs. The Recorded Music segment involve the acquisition of sound recording catalogs and the discovery and development of recording artists and the marketing, distribution, sale and licensing of the music catalog.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.